Bookmark
Forward
QuickView for Dactinomycin (compound)
PubChem
| Name: | Dactinomycin |
|---|---|
| PubChem Compound ID: | 2019 |
| Description: | A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) |
| Molecular formula: | C62H86N12O16 |
| Molecular weight: | 1255.42 g/mol |
| Synonyms: |
Dactinomycin [USAN:BAN]; CBiol_002056; 3H-phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethy; CCRIS 9; NCI-C04682; 2-Amino-N,N'-bis[hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-1)(1,4,10,13)oxatetraazacyclohexadecin-10-yl]-; Actinomycin X1; NSC 3053; l-3-oxo-; 2-Amino-N,N'-bis-[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-1)(1,4,7,10,13)oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarb.
show more » |
DrugBank
Identification
| Name: | Dactinomycin |
|---|---|
| Name (isomeric): | DB00970 |
| Drug Type: | small molecule |
| Description: | A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) |
| Synonyms: |
AD; Antibiotic From Streptomyces Parvullus; Dactinomicina [INN-Spanish]; Dactinomycinum [INN-Latin]; Dactinomycine [INN-French]
|
| Brand: | ACT, Chounghwamycin B, Actinomycin I, ACT D, Actactinomycin a Iv, Actinomycin C1, Actinomycindioic D Acid, Dilactone, Dilactone Actinomycindioic D Acid, Dactinomycin D, Meractinomycin, Actinomycin 11 Cosmegen, Lyovac Cosmegen, Actinomycin X 1, Oncostatin K, Cosmegen, ACTO-D, HBF 386 Meractinomycin, Oxamide, Actinomycin I1, Actinomycin Iv, Actinomycin Aiv, Dilactone Actinomycin D Acid, Actinomycin 7, ACTINOMYCIN D |
| Category: | Protein Synthesis Inhibitors, Anti-Bacterial Agents, Antineoplastic Agents, Antibiotics, Antibiotics, Antineoplastic, Nucleic Acid Synthesis Inhibitors |
| CAS number: | 50-76-0 |
Pharmacology
| Indication: | For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen |
|---|---|
| Pharmacology: |
Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are ...
show more » |
| Mechanism of Action: | Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis. |
| Absorption: | poorly absorbed from gastrointestinal tract |
| Protein binding: | 5% |
| Biotransformation: | hepatic |
| Half Life: | 36 hours |
| Toxicity: | hepatoxicity |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Transporters
